Shedding Light on PARP Inhibitor Response through Functional Imaging.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 36700799.
- Also identified by DOI 10.1158/1078-0432.CCR-22-3711 and PMC identifier 10106371.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Functional PET imaging using a PARP inhibitor (PARPi) analog may serve as an early, dynamic biomarker of response to PARPi therapy in high-grade serous ovarian cancer. Clinically, this could help to rapidly identify PARPi nonresponders, thereby maximizing efficacy and avoiding toxicities of futile treatments. See related article by Pantel et al., p. 1515.
Medical subject headings
- Ovarian Neoplasms
- Antineoplastic Agents